Expertise in
41
conditions

Dr. Joseph Drabick

Hematology
Penn State Children's Hospital
600 Univ Dr, 
Hershey, PA 
Expertise in
41
conditions
Penn State Children's Hospital
600 Univ Dr, 
Hershey, PA 

Overview

Joseph Drabick is a Hematologist practicing medicine in Hershey, Pennsylvania.

Dr. Drabick is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Melanoma, Adult Soft Tissue Sarcoma, Fibrosarcoma, Tissue Biopsy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 67 peer reviewed articles and participating in 11 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in PA

Hospital Affiliations

Penn State Health Lancaster Medical Center
Milton S Hershey Medical Center
Penn State Health Holy Spirit Medical Center
Wellspan Chambersburg Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Penn State Children's Hospital
600 Univ Dr, Hershey, PA 17033
Other Locations
Penn State Cancer Institute-Infusion Centers
400 Univ Dr, Hershey, PA 17033

Additional Areas of Focus

Dr. Drabick has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: May 29, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
Enrollment Status: Suspended
Publish Date: July 02, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Pembrolizumab, Propranolol Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

67 Total Publications

Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy - active Phytochemicals and In Vivo Molecular Targets.
Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy - active Phytochemicals and In Vivo Molecular Targets.
Journal: Pharmaceutical research
Published: September 20, 2024
Similar Doctors
Expertise in
14
conditions
Dr. Efrat Dotan
Hematology | Oncology
Expertise in
14
conditions
Dr. Efrat Dotan
Hematology | Oncology
Referral may be required
Before you request

LG Health Physicians Hematology And Medical Oncology

2102 Harrisburg Pike, 
Lancaster, PA 
 (20.5 miles away)
717-544-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Efrat Dotan is a Hematologist and an Oncologist practicing medicine in Lancaster, Pennsylvania. Dr. Dotan is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Dotan is board certified in Medical Oncology, 2010. Dr. Dotan is currently accepting new patients.

Expertise in
6
conditions
Dr. Jonathan Bernstein
Hematology | Oncology
Expertise in
6
conditions
Dr. Jonathan Bernstein
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (2.1 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances

Jonathan Bernstein is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Bernstein is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Chronic Spontaneous Urticaria (CSU), Hemophilia A, Mast Cell Activation Syndrome (MCAS), and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Expertise in
21
conditions
Dr. Nelson Yee
Hematology | Oncology
Expertise in
21
conditions
Dr. Nelson Yee
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (2.1 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nelson Yee is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Yee is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Joseph Drabick

How do I make an appointment with Dr. Joseph Drabick?

You can book an appointment with Dr. Joseph Drabick by calling their office at 800-243-1455. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph Drabick a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph Drabick is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph Drabick specialize in?

While Dr. Joseph Drabick is a Hematology, they have specific expertise in Melanoma, Adult Soft Tissue Sarcoma, and Fibrosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph Drabick participate in research or clinical trials?

Yes. Dr. Joseph Drabick has published 67 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Joseph Drabick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph Drabick accept my insurance?

Dr. Joseph Drabick accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-243-1455 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Drabick's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 30 Advanced Conditions
View All 60 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile